Literature DB >> 3818577

Analyses of prealbumin mRNAs in individuals with familial amyloidotic polyneuropathy.

S Mita, S Maeda, K Shimada, S Araki.   

Abstract

The distribution of prealbumin mRNA in various tissues of a control subject and an individual with familial amyloidotic polyneuropathy (FAP) was investigated using a cloned human prealbumin cDNA as a probe. Prealbumin mRNAs were detected in the total RNAs from liver and choroid plexus of brain, but not in those from brain, heart, kidney, and thyroid gland. The level of prealbumin mRNA in the choroid plexus was about 100-fold higher than that in the liver. We detected no differences in the sizes of prealbumin mRNAs in the liver and choroid plexus of the control subject, or in those of the individual with FAP, and found that the prealbumin mRNAs in these tissues had been transcribed from a common transcription initiation site. The levels of prealbumin mRNAs in the livers of four control subjects and those of six individuals with FAP were much the same. Because all the individuals with FAP so far examined were heterozygous for the prealbumin gene, carrying one normal and one mutant gene, the levels of the normal and mutant prealbumin mRNAs in the liver and the brain tissue containing choroid plexus were separately estimated and were found to be approximately equal.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3818577     DOI: 10.1093/oxfordjournals.jbchem.a121826

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  9 in total

1.  A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.

Authors:  Sungwook Choi; Jeffery W Kelly
Journal:  Bioorg Med Chem       Date:  2010-12-30       Impact factor: 3.641

2.  Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.

Authors:  M M Sousa; I Cardoso; R Fernandes; A Guimarães; M J Saraiva
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin.

Authors:  Jacquelyn L S Hanson; Marios Arvanitis; Clarissa M Koch; John L Berk; Frederick L Ruberg; Tatiana Prokaeva; Lawreen H Connors
Journal:  Circ Heart Fail       Date:  2018-02       Impact factor: 8.790

4.  The effect of tafamidis on the QTc interval in healthy subjects.

Authors:  Karen J Klamerus; Eric Watsky; Robert Moller; Ronnie Wang; Steve Riley
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

5.  Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.

Authors:  Giampaolo Merlini; Violaine Planté-Bordeneuve; Daniel P Judge; Hartmut Schmidt; Laura Obici; Stefano Perlini; Jeff Packman; Tara Tripp; Donna R Grogan
Journal:  J Cardiovasc Transl Res       Date:  2013-10-08       Impact factor: 4.132

6.  Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors.

Authors:  Nojoon Myung; Stephen Connelly; Boyoung Kim; Sung Jean Park; Ian A Wilson; Jeffery W Kelly; Sungwook Choi
Journal:  Chem Commun (Camb)       Date:  2013-08-29       Impact factor: 6.222

7.  Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity.

Authors:  Joel Buxbaum; James Koziol; Lawreen H Connors
Journal:  Amyloid       Date:  2008-12       Impact factor: 7.141

8.  Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.

Authors:  Genki Suenaga; Tokunori Ikeda; Yoshihiro Komohara; Koutaro Takamatsu; Tatsuyuki Kakuma; Masayoshi Tasaki; Yohei Misumi; Mitsuharu Ueda; Takaaki Ito; Satoru Senju; Yukio Ando
Journal:  PLoS One       Date:  2016-10-03       Impact factor: 3.240

9.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Ole B Suhr; Peter J Dyck; William J Litchy; Raina G Leahy; Jihong Chen; Jared Gollob; Teresa Coelho
Journal:  BMC Neurol       Date:  2017-09-11       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.